Immune Response ist wieder da ! - 500 Beiträge pro Seite

[AndererKostolany]

Heute gleich mal 25% plus!!
Ich glaube die shorties decken sich ein!!

[strongman]

hi,
was meinst du,sollte man drin bleiben?
bin seit 8,20 dabei.
gabs irgentwelche neuen news.
die von letzte woche kenne ich

strongman

[e.broker]

also wenn es heute news gegeben hätte, dann würde ich bei diesem markt sagen raus.
aber es gab keine news!
da ich aber davon ausgehe das bevorstehende news der grund für den anstieg waren und ich morgen eine rally am nasdaq erwarte, würde ich investiert bleiben (zumindest noch den grund für den anstieg abwarten).
das war heute eine megafette performance von imnr (man bedenke das umfeld) und ich rechne mit megafetten news.
um dich abzusichern kannst du natürlich auch einen stopploss setzen.
so long, be strong
grüsse
ebroker

[iaras]

ihr pfeiffen,
seit monaten kaufe ich nur aktien aufgrund eurer beiträge. so auch imnr. und endlich geht die aktie wieder nach oben, und ihr schnarchzapfen pennt.
geht es jetzt endlich los?

[xybernauty]

hallo iaras,
Du solltest nicht Alles kaufen, sondern Dich über Deine Investments informieren. Allerdings glaube ich, hast Du mit IMNR eine gute Wahl getroffen. Du solltet allerdings bei IMNR mindestens über 2 - 3 Jahre drin bleiben.
In der Strategie dieser Firma steckt das eigentliche Potential.
Mit den Produkten, sollte IMNR erfolgreich sein, wird das Immunsystem
des Menschen widerstandsfähig gegen Aids, Krebs usw..
Das bedeutet, nach meiner Interpretation, daß solange der Patient die Produkte dieser Firma kauft und sich damit behandeln läßt, wird dieser Patient leben. Die Frage des Preises stellt sich dann nicht mehr. Sollte es IMNR gelingen, diese Produkte herzustellen, können diese zu jedem Preis und über lange Zeit an Millionen verkauft werden.
Das Ganze ist zwar pervers aber die eigentliche Fantasie in diesem Wert! Ähnlich geht auch ADVR vor.

Viel Glück und fette Beute !
Xybernauty

[strongman]

hi ebroker u die anderen,
jo,ich denke ich warte auch nochmal ab was da kommt.
vielleicht sind 15$ drin,aber dann bin ich draußen,
denn das ging dann zu schnell.
langfristig sind die bios natürlich top,keine frage.
auf jeden fall wird eine nachricht kommen oder es waren nur irgentwelche gerüchte,aber
diese umsätze lassen was gutes erwarten
gute geschäfte

strongman

[Andrax]

das ist wahrscheinlich der grund ...
palm beach, florida 28.6.-1.7.2000



Meeting objectives
The objectives of the First International Conference on Vaccine Development and Immunotherapy in HIV are as follows:

1. To discuss the most recent scientific developments and vaccine trial data on HIV
2. To identify novel approaches and key technologies critical to vaccine development
3. To review the immunopathogenesis of HIV
4. To discuss new targets for HIV immunotherapy
5. To discuss ethical and economic factors influencing vaccine development
6. To formulate key research questions for future investigation

Target audience

This conference is primarily aimed at physicians and researchers involved in HIV vaccine and immunology research. General practitioners, nurse practitioners, healthcare/community workers and pharmaceutical company personnel are also invited to attend.

Program session topics:

Immunopathogenesis
Viral clearance and strategies of immune evasion
Immunotherapy
gp120 structure and immunogenicity
Novel vaccine vectors
Animal models and the correlates of protection
Prophylactic vaccine trials
Program
Wednesday 28 June

08.30: Breakfast
09.30: Registration
11.00: Welcome

SESSION 1. Immunopathogenesis
11.15
Plenary presentation 1. Acute SIV and HIV infection: life in the fast lane in a slow infection
Ashley Haase

11.40
Plenary presentation 2. The short- and long-term effects of highly pathogenic SHIV infections of rhesus macaques
Malcolm Martin

12.05
HIV-1 immunopathogenesis in human lymphoid tissue correlates with co-receptor utilization
Svetlana Glushakova

12.20
Innefficient inhibition of replication of HIV-1 by immunodominant CTL clones obtained from rapid progressors
Christine Hay

12.35
Dynamics of acute SIV/SHIV/HIV infections and immune responses: a quantitative analysis by mathematical modelling
Dimiter Dimitrov

12.50
Discussion

13.10
Lunch

SESSION 2. Viral clearance and strategies of immune evasion

14.30
Plenary presentation 1. Levelling the playing field: insights into retroviral pathogenesis and vaccine development from transient post-inoculation treatment of SIV-infected macaques
Jeff Lifson

14.55
Acute viral escape from cytotoxic T lymphocytes: implications for HIV vaccine design
Todd Allen

15.10
Combined presentation
Effect of HIV-1 Nef on the antiviral function of HIV-1-specific cytotoxic T lymphocytes

In vitro modelling of HIV-1 escape from cytotoxic T lymphocytes
Otto Yang

15.40
Break

16.10
Immune reconstitution on non-nucleoside based HAART
Nesrina Imami

16.25
Discussion

16.45
Overview of poster data – Organizing Committee

17.00
Session close

17.30
Wine and cheese reception

Poster Session 1
Presenting authors of all abstracts from Session topics 1–3 will be available to answer questions

19.00
CLOSE

Thursday 29 June

8.00
Breakfast

SESSION 3. Immunotherapy

9.00
Plenary presentation 1. Enhancement of HIV-specific CD4 and CD8 T cell immune responses with a gp120-depleted, whole-killed immunogen (Remune): implications for therapy and prevention
Ron Moss

9.25
Plenary presentation 2. The induction of ‘missing’ anti-HIV immune responses in HIV-infected individuals by means of immunization
Fred Valentine

9.50
Results of a double-blind, adjuvant-controlled trial of HIV-1 immunogen (Remune) in asymptomatic HIV-1-infected Thai volunteers at weeks 40 and 88
Vina Churdboonchart

10.05
Identification and immunological evaluation of conserved HIV-1 cytotoxic T lymphocyte epitopes for use in prophylactic and therapeutic vaccines
Mark Newman

10.20
A multi-component DNA vaccine can stimulate specific immunity and influence viral load in the context of PMPA immunotherapy in SIV-infected rhesus macaques
Jean Boyer

10.35 Redirecting the immune response to HIV-1 associated carbohydrate antigens
Thomas Kieber-Emmons

10.50
Discussion

11.10
Break

SESSION 4. gp120 structure and immunogenicity

11.40
Plenary presentation 1. The in vivo anti-HIV-1 activity of human neutralizing antibodies
Dennis Burton

12.05
Plenary presentation 2. Effects of envelope modifications on the properties of SIVmac239
Ron Desrosiers

12.20
A modified HIV-1 envelope immunogen elicits neutralizing antibodies against heterologous primary HIV-1 isolates
Leo Stamatatos

12.35
Revisiting whole inactivated HIV-1 vaccines: imunogenicity studies in mice after vaccination with gp120-containing killed virions
Kathie Grovit-Ferbas

12.50
HIV envelope glycoprotein-CD4-co-receptor complexes: implications for entry mechanisms and vaccine development
Xiaodong Xiao

13.05
Discussion

13.25
Lunch

14.30
Special workshop. Trials in developing countries:
Andrew McMichael
Hilton Whittle
William Heyward
Rose McCullough/Bill Snow

16.30
Session close

17.30 Poster Session 2
Presenting authors of all abstracts from Session topics 4–7 will be available to answer questions

18.30
CLOSE

Friday 30 June

9.00
Breakfast

SESSION 5. Novel vaccine vectors

10.00
Plenary presentation 1. Protection against SIV infection in rhesus macaques immunized with herpes simplex virus recombinant vector strains
David Knipe

10.25
Plenary presentation 2. A single dose, adeno-associated virus vector SIV vaccine elicits long-lived immune responses in macaques
Phil Johnson

10.50
Alphavirus replicon particles that infect immature human dendritic cells with high efficiency and stimulate robust immune responses against HIV antigens
Thomas Dubensky

11.05
Enhancing primary and secondary cellular immune responses against HIV-1 Gag by DNA expression vectors that target Gag antigen to the secretory pathway
Jian-Tai Qui

11.20
Break

11.50
Vaccine strategies using prime-boost immunization for the effective induction of cell-mediated immunity against HIV-1
Ian Ramshaw

12.05
Improved potency DNA vaccines against HIV
Jeffrey Ulmer

12.20
Discussion

12.40
Lunch

SESSION 6. Animal models and the correlates of protection

14.00
Plenary presentation 1. Title to be confirmed
Paul Johnson

14.25
Plenary presentation 2. Strategies for vaccine-induced protection against rectal infection
Martin Cranage

14.50
Preferential induction of CTL and type 1 T helper cell responses in rhesus macaques following multiple DNA immunizations and protection from heterologous SIV challenge
Mary Wu

15.05
Characterizing effector and memory functions by ex vivo analysis of SIV Ag-specific, MHC-restricted rhesus T lymphocytes
Ursula Esser

15.20
Break

15.50
Potential use of nef-deleted SHIV derived from a non-pathogenic SHIV as a live-attenuated vaccine that protects macaques against challenge infection by a heterologous pathogenic SHIV
Mary Hayami

16.05
DNA vaccination in macaques by a full genome HIV-1 plasmid that produces non-infectious virus particles
Wataru Akahata

16.20
Discussion

16.45
Close

19.00
Conference Dinner

Saturday 1 July

8.30
Breakfast

SESSION 7. Prophylactic clinical trials

9.30
Plenary presentation 1. Title to be confirmed
Phil Berman

9.55
Use of inactivated SIV and HIV as vaccines and in vitro reagents
Larry Arthur

10.10
Development of a candidate HIV-1 subtype A vaccine using a consensus sequence from recent prevalent and incident HIV-1 infections
Dennis Ellenberger

10.25
Planning a Phase 1 HIV-1 vaccine trial in West Africa: immunization with DNA and Modified Vaccinia Ankara to elicit a mucosal CTL response
Tom Blanchard

10.40
Development of Nigerian-based HIV-1 vaccine: strain selection
Simon Agwale

11.05
Break

11.25
Whole-killed virus vaccines prepared by the action of Aldrithiol-2
Elena Chertova

11.45
Discussion

12.10
CONFERENCE OVERVIEW/CLOSING REMARKS

12.30
CONFERENCE CLOSE